CRISPR Therapeutics AG

NAS:CRSPHealthcareCBOEFTSE:MRUTNASDAQ:NBI

$49.88−0.32%At closeAt close · Wed 21 Oct · ≈ AED 183.18 · Market cap $4.82B · Next earnings Wed 4 Nov · Extended $50.10 +0.44%

Ratio	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	Current · undated	YoY
Gross margin	−37,369.7%	88.9%	−25,186.7%	64.8%	−215.0%	−6,537.0%	—	—
Operating margin	−49,295.5%	40.9%	−154,394.7%	−60.1%	−1,333.0%	−16,191.4%	−16,191.4%	+0.0 pts
Net margin	−48,520.9%	41.4%	−149,122.7%	−41.5%	−1,046.4%	−16,569.8%	−16,569.8%	+0.0 pts
EBITDA margin	−48,018.2%	43.5%	−143,653.2%	−35.4%	−981.2%	−15,911.3%	—	—
Return on equity	−21.0%	15.7%	−34.7%	−8.2%	−19.0%	−30.3%	−30.3%	+0.0 pts
Return on assets	−19.1%	13.7%	−29.0%	−6.9%	−16.3%	−25.7%	−25.7%	+0.0 pts
Return on capital employed	−20.4%	14.2%	−31.7%	−10.5%	−21.7%	−26.9%	—	—
Debt / equity	0.0×	0.1×	0.1×	0.1×	0.1×	0.2×	0.2×	+0.0%
Debt / assets	3.4%	8.2%	10.9%	10.7%	10.0%	17.4%	—	—
Interest coverage	0.0×	0.0×	0.0×	0.0×	0.0×	0.0×	—	—
Current ratio	18.2×	20.2×	15.3×	17.5×	22.1×	13.3×	13.3×	+0.0%
Quick ratio	18.2×	20.2×	15.3×	17.5×	22.1×	13.3×	—	—
Cash ratio	12.4×	7.7×	1.7×	3.6×	3.4×	2.4×	2.4×	+0.0%
Asset turnover	0.0×	0.3×	0.0×	0.2×	0.0×	0.0×	—	—
Receivables turnover	0.1×	2,993.7×	—	1.9×	1.4×	—	—	—
Dividend payout	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	—	—